Parini Michael, EVP, CL&AO, subtracted 4,250 shares of Vertex Pharmaceuticals Incorporated (VRTX) from its portfolio at the rate of $179.11 per share valuing $761,239 on Jul 05. The insider left behind 35,003 shares of the company to its portfolio. Before making a move on any particular stock, readers often pay close attention to support and resistance markers. The last reported price for shares of Vertex Pharmaceuticals Incorporated (VRTX) was $176.01. Currently, the 1st Resistance Point for this stock is $179.00, with a 2nd Resistance Point sitting at $181.99. Meanwhile, this company’s stock has a 1st Support Level at $172.88 and a 2nd Support Level at $169.75. Vertex Pharmaceuticals Incorporated (VRTX) stock has lost -$7.25, or -3.96%, in the past five days. In the last full month, these shares have gained $4.01, or 2.33%. In the past three months, this stock’s price has fallen by -$9.11, or -4.92%. This year-to-date, Vertex Pharmaceuticals Incorporated (VRTX) shares have gained $10.30, or 6.22%.
Analyzing price projection indicators is a helpful way to determine whether a potential stock buy is a wise choice for profits in the short term, medium term, and long term. For Vertex Pharmaceuticals Incorporated (VRTX) stock, 40% of short-term indicators suggest that these shares are a “ Buy .” Meanwhile, 25% of medium-term indicators point to this stock being a “ Buy .” Looking further ahead, 67% of long-term indicators suggest that this stock is a “ Sell .”
With 256,121 K shares outstanding, this company currently has a market capitalization of $45,079,856K. Vertex Pharmaceuticals Incorporated (VRTX) generates $3,048 M in annual sales, amounting to annual net income of $2,097 M. This stock has generated a 1-Year Total Return of 0.57%, a 3-Year Total Return of 95.11%, and a 5-year Total Return of 81.08%. This stock’s 5-Year Dividend Growth is 0.00%. Its Annual Dividend Yield is 0.00%, and its Annual Dividend Rate is 0.00.
In the most recently-reported fiscal quarter, which ended in Mar-19, Vertex Pharmaceuticals Incorporated (VRTX) reported earnings of $1.14 per share. Wall Street analysts, on average, were expecting the company to report earnings of $0.97 per share, representing a 0.17 difference and 17.15% surprise. In the previous quarter ending in Dec-18, the reported earnings of $1.30 represented a 0.24 difference from the consensus estimate calling for $1.06 per share, which was a 22.38% surprise.
For the current fiscal quarter, which is set to end in 06/2019, the average earnings estimate is $0.75 per share. This estimate came from a total of 7 Wall Street Analysts. Of those market experts, the high estimate was $0.85 and the low estimate was $0.71. In the year-ago quarter, Vertex Pharmaceuticals Incorporated (VRTX) generated per-share earnings of $0.62. If the analysts are correct about the current quarter’s earnings, the growth will be +20.97% .
Turning our focus now to insider trading activity, there have been 17 purchases (240,121 shares in total) and 48 sale (244,304 shares in total) in the last 3 months. In the last 6 months, there have been 56 insider buys amounting to 540,454 shares and 116 insider sales amounting to 602,751 shares. In the past full year, 92 insider purchases were made (involving 665,255 shares) and 171 insider sell-offs equivalent to 731,225 shares.
Moving onto liquidity, Vertex Pharmaceuticals Incorporated (VRTX) has a Current Ratio of 3.43, a Quick Ratio of 3.32 and a Cash Ratio of 2.83. Looking at this company’s capital structure, its Total Debt to Total Equity is 13.33, its Total Debt to Total Capital is 11.76, and its Total Debt to Total Assets is now 9.47. Looking even further ahead into the future, its Long-Term Debt to Equity is 13.11 and its Long-Term Debt to Total Capital is 11.57.